PURE Bioscience develops and commercializes antimicrobial products built on its patented silver dihydrogen citrate (SDC) technology. Company updates center on SDC-based food safety and sanitation applications for food and beverage manufacturing, produce processing, transportation sanitation, and janitorial and consumer cleaning channels.
Recurring news includes fiscal financial results, net product sales trends, distribution partner activity, and product applications such as PURE Control for direct food-contact use and PURE Hard Surface for dairy and beverage membrane treatment. PURE also reports governance and leadership changes tied to its commercial operations and regulatory affairs functions.
PURE Bioscience reported a significant 256% increase in net product sales for Q1 FY2020, totaling $1,417,000, up from $398,000 in the same quarter last year. The net loss narrowed to $180,000, compared to $1.1 million in Q1 FY2019, with net income (excluding share-based compensation) at $49,000. The gross margin decreased to 55% from 61%, attributed to lower-margin products. The company expanded its distribution network across various food safety sectors and is gaining traction in the federal procurement space.